Merck: EU approves Winrevair for PAH

(CercleFinance.com) - Merck announced on Monday that the European Commission has granted it marketing authorization for Winrevair in the treatment of pulmonary arterial hypertension (PAH).


The American pharmaceutical group explains that Brussels' approval concerns the combination of the drug with standard therapies for the disease in adult patients with WHO functional class II and III, with the aim of improving their exercise capacity.

This is the first authorization granted to an activin signaling pathway inhibitor approved to treat PAH in the European Union, Iceland, Liechtenstein and Norway in the field.

According to Merck, Winrevair improves the balance between pro- and anti-proliferative signals in order to modulate pulmonary vascular proliferation, in particular by inducing cellular changes associated with thinner vascular walls.


Copyright (c) 2024 CercleFinance.com. All rights reserved.